The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

JANUARY 4, 2021

for expanding activities in the US with its initial focus on facilitating clinical development. Outline of the new company (1) Company name: Meiji Pharma USA Inc. (2) Location: 500 Frank W. (6) Established: 4 July, 2020 (7) Shareholding structure: Wholly-owned by Meiji Seika Pharma Co.,

Pharmaceutical Companies 40

Pharmaceutical Companies Clinical Development Pharmaceuticals Clinical Research 40

The Pharma Data

JANUARY 3, 2021

04, 2021 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that its subsidiary, InspirMed Inc., SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials Disease 52

The Pharma Data

NOVEMBER 10, 2020

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. By joining Innovent, Dr. Liu will be responsible for global R & D, pipeline strategy, business development and international operations.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

Altus Drug Development

JUNE 28, 2022

Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine? To comply with the law.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Doctors Treatment 52

The Pharma Data

DECEMBER 31, 2020

where he led global clinical development programs including clinical strategy, clinical development, and regulatory affairs. He also previously served as Global CMO at Taiho Pharmaceutical Company, Ltd. Benedetti most recently served as chief medical officer for Apollomics, Inc.,

Engineering 52

Engineering Pharmaceuticals Clinical Development Virus 52

The Pharma Data

MARCH 29, 2022

“We believe in advancing health through partnerships and are excited to embark on this journey, strengthening our ability to create a positive impact on patient lives,” shared Uli Brödl, senior vice president, global clinical development and operations at Boehringer Ingelheim. About Veeva Systems.

Therapies 52

Therapies Clinical Development Pharmaceutical Companies Research 52

The Pharma Data

SEPTEMBER 25, 2020

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Interim analysis from Phase 1/2a First-in-Human trial supports further clinical development of investigational vaccine candidate JNJ-78436735 (also known as Ad26.COV2.S). Source link.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 24, 2021

The Company currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures. About Citius Pharmaceuticals, Inc.

Marketing 40

Marketing Pharmaceuticals Pharmaceutical Companies Production 40

Molecule Blog

MARCH 17, 2023

For instance, many of the top-selling therapeutics available today were originally developed in academia and had to navigate the difficult path of translation. The process of transforming a therapeutic or technology from the research and development stage into a market-ready product or service is intricate and laden with obstacles.

Engineering 52

Engineering Research Clinical Trials Government 52

The Pharma Data

JANUARY 27, 2021

28, 2021 /PRNewswire/ — CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.). ET ) to discuss the results and next steps in clinical development of BI-1206. The Company’s validated, proprietary F.I.R.S.T . ROCKVILLE, Md. , and BEIJING , Jan. Nasdaq: CASI), a U.S. CET ( 11:30 a.m.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Conversations in Drug Development Trends

MAY 14, 2024

As the strategists for Worldwide Clinical Trials’ rare disease sponsors, we design customized solutions that make a difference in achieving successful outcomes. Our approach is informed by our combined 30+ years in rare disease clinical development and our time in various stakeholder roles, such as scientists, CRAs, and project managers.

Disease 52

Disease Clinical Trials Trials Pharmaceutical Companies 52

The Pharma Data

JULY 29, 2021

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Eisai Co.,

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

The Pharma Data

JANUARY 31, 2021

We have established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Targeted Protein Degradation Drugs Disease 52

The Pharma Data

DECEMBER 8, 2020

The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases. Noema Pharma .

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

OCTOBER 18, 2020

Oncopeptides plans to initiate clinical development of OPD5 with an open-label phase 1, dose escalation study on safety and tolerability of OPD5 as a myeloablative regimen followed by Autologous Stem Cell Transplantation in patients with relapsed refractory multiple myeloma. About Oncopeptides.

FDA 40

FDA Drugs Pharmaceutical Companies Treatment 40

The Pharma Data

DECEMBER 17, 2020

In addition, TLC is preparing for scale-up production of TLC590, as for complex lipid products, the manufacturing process and batch size used in pivotal clinical trials and New Drug Application submission must be the same as future commercial batches. Patient enrollment of EXCELLENCE pivotal trial reaches 98%.

Clinical Trials 40

Clinical Trials Trials Pharmaceutical Companies Clinical Pharmacology 40

The Pharma Data

OCTOBER 22, 2020

The Company intends to use the net proceeds from this offering to support its planned New Drug Application submission for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with quinolone-resistant pathogens, the continued clinical development of sulopenem, and for working capital and general corporate purposes.

Clinical Trials 40

Clinical Trials Pharmaceutical Companies Clinical Development Pharmaceuticals 40

The Connected Lab

APRIL 8, 2020

It is reported that every one of the major pharmaceutical companies has announced a partnership with at least one AI-based drug development company, but how is AI being used to facilitate drug development? By utilizing these products, all data can be stored in one central system, facilitating machine learning.

Pharma Companies 52

Pharma Companies Laboratories Drugs FDA Approval 52

The Pharma Data

NOVEMBER 30, 2020

In return, Sosei Heptares will receive an upfront payment of US$10 million in the form of cash consideration and Biohaven common shares, research funding, and is eligible to receive additional development, regulatory and commercialization milestone payments of up to US$370 million. Vlad Coric , M.D., GPCR – G protein-coupled receptors.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

NOVEMBER 19, 2020

Retterath joins Spark from Bain & Company, where he served as a partner in the healthcare practice for a decade. He focused on corporate and business unit strategies, organizational transformations, product launches, growth strategies and new market entries. where he led the company’s operations during a period of rapid growth.

Laboratories 52

Laboratories Research Laboratories Science Organic Chemistry 52

The Pharma Data

APRIL 6, 2021

The new data reaffirm Bayer’s continued efforts to demonstrate the clinical impact a precision medicine approach can have on patients. While local labels might differ, the product is approved for adult and pediatric patients with solid tumors that harbor a NTRK gene fusion and have no satisfactory alternative treatments.

Research 52

Research Small Molecule Treatment Clinical Trials 52

The Pharma Data

NOVEMBER 19, 2020

We have established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Genentech (Roche), Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

The Pharma Data

JUNE 25, 2021

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Eisai Co.,

Disease 40

Disease Treatment Therapies FDA 40

The Pharma Data

JANUARY 4, 2021

Shinichi Tamura , Chairman, President and CEO of Sosei Heptares, commented: “We are delighted to regain rights to this portfolio of novel subtype-selective muscarinic receptor agonists (M 4 , M 1 and dual M 1 /M 4 agonists), including several clinical and preclinical candidates with substantial data associated.

Licensing 40

Licensing Licensing Clinical Trials Disease 40

The Pharma Data

JULY 8, 2021

is a leading global pharmaceutical company headquartered in Japan. Leveraging the experience gained from the development and marketing of a treatment for Alzheimer’s disease, Eisai aims to establish the “Eisai Dementia Platform.” We routinely post information that may be important to investors on our website at www.biogen.com.

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

The Pharma Data

JANUARY 17, 2021

“This result provides a foundation for a clinical development program using higher doses of setanaxib across a variety of orphan indications. From this, Genkyotex has developed a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. Significant improvement in fatigue was also achieved.

Trials 40

Trials Clinical Trials Pharmacokinetics Small Molecule 40

The Pharma Data

DECEMBER 29, 2020

NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

The Pharma Data

DECEMBER 21, 2020

Promising leads will be progressed using the partners’ complementary discovery skills, resources and development capabilities for subsequent development and commercialization. This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

Agency IQ

FEBRUARY 12, 2024

The pilot focused on identifying commonalities across products using Adeno-Associated Virus (AAV) vectors to reduce duplication of efforts across individual therapeutic programs and to encourage the field to move away from the current “one-disease-at-a-time approach.”

FDA 40

FDA Therapies Clinical Trials Disease 40

The Pharma Data

JANUARY 14, 2021

Clinical Development – Pipeline Review. The presentations will be made available on the company’s website after the end of the meeting. . 3:40pm. Setanaxib – Applications in Oncology. End.

Clinical Trials 40

Clinical Trials Disease Hospitals International 40

The Pharma Data

NOVEMBER 15, 2020

a publicly traded biopharmaceutical company, from 2012 to December 2019, managing its international, legal, quality, intellectual property and compliance functions, after serving in other executive roles at Acorda starting in 2004. Before joining Acorda, Ms. Shah also serves on the boards of several civic organizations and initiatives.

Clinical Trials 40

Clinical Trials Trials Production Therapies 40

Drug Target Review

SEPTEMBER 19, 2024

IRL1117 is expected to be ready to move into clinical development at the end of 2024/first half 2025. She has extensive experience in executive management, drug development, regulatory affairs and licensing with major international pharmaceutical companies, including in the field of neurodegenerative diseases.

Disease 52

Disease Drugs Treatment Drug Development 52

The Pharma Data

JANUARY 25, 2021

. “This marks our second strategic agreement with Asieris, a well-run and well-capitalized company that is executing ahead of plan on the clinical development of Cevira ®, which we licensed to them in July 2019. Founder and CEO of Asieris. ” About Photocure ASA.

Licensing 40

Licensing Licensing Clinical Development Pharmaceutical Companies 40

The Pharma Data

JANUARY 25, 2021

agree to place handheld Ceribell Rapid Response EEG systems in hospitals in connection with its Phase 3 RSE clinical trial. –( BUSINESS WIRE )– Marinus Pharmaceuticals, Inc. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc. Marinus and Ceribell, Inc. RADNOR, Pa.–(

Clinical Trials 40

Clinical Trials Trials Hospitals Pharmaceutical Companies 40

The Pharma Data

JANUARY 25, 2021

The Company will manufacture and supply Hexvix, and receive a transfer price from Asieris representing a markup on product provided under the Agreement. Photocure will also receive royalties on product sales. but with a healthcare system that is still developing. ” said Kevin Pan Ph.D., Founder and CEO of Asieris.

Clinical Development 40

Clinical Development Licensing Licensing Production 40

Advarra

AUGUST 10, 2023

The Orphan Drug Act creates incentives for developing orphan drugs to treat such diseases. However, recent advancements in the clinical use of recombinant DNA (rDNA) technology creates opportunities for changing this calculation and addressing a great, unmet medical need. “I

Drug Development 52

Drug Development Disease Therapies Engineering 52